News

RadioMedix presented at the 2018 BIO Investor Forum in San Francisco

Posted by RadioMedix . on

RadioMedix presented at the 2018 BIO Investor Forum in San Francisco

(Houston, December 14, 2018). RadioMedix Inc has been selected by the National Cancer Institute (NCI) Small Business Innovation Research Development Center (SBIR) to participate in 2018 BIO Investor Forum. The company received federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services (HHSN261201600015C, HHS261201800048C/75N91018C00048)  for the development of radiotherapeutic alpha-emitter labeled agents. Dr. Izabela Tworowska, Chief Science Officer of RadioMedix, presented an overview of the company pipeline, the financial growth of RadioMedix, and status of the clinical development of radiotheranostic drugs. The presentation was sponsored by NCI SBIR Development Center’s Investor Initiatives program....

Read more →

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

Posted by RadioMedix . on

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

Houston (TX U.S.), Courbevoie (France),  November 13th, 2018. RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company) announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AlphaMedixTM for the treatment of neuroendocrine tumors (NETs).  AlphaMedixTM is a 212Pb-labeled somatostatin analogue used for the targeted alpha therapy (TAT) of neuroendocrine tumors (NETs). “TAT has brought new hope to our patients with cancer, and the range of available therapies in this area will only increase in the near future. We are pleased to conduct the first TAT clinical trial in the...

Read more →

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

Posted by RadioMedix . on

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

Houston (TX, USA) and Garching (Germany), July 25, 2018 – RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a specialized radiopharmaceutical group of companies announced today that ITM’s subsidiary, Isotope Technologies Garching GmbH (ITG), and RadioMedix signed a manufacturing and supply agreement for the production of the next generation of Ge-68/Ga-68 (Germanium-68/Gallium-68) generators at the new RadioMedix Spica Center (RSC) in Houston, Texas. RSC is a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility dedicated to late-stage investigational and commercial stage radiopharmaceuticals. The medical radionuclide Gallium-68, which is produced in Ge-68/Ga-68 generators, is used in the field of Targeted Radionuclide Therapy to...

Read more →